Clinical trials: LAM
Chronic Hepatitis B
Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients
The aim is to investigate the best treatment regime of PEG-Intron A and lamivudine combination in terms of viral clearance in chronic hepatitis B patients.
- Trial name
- NCT00226447
- Testing
- Pegylated Interferon, Lamivudine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
HIV Infections
3TC (Lamivudine; GR109714X) Open-Label Program
To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies.
- Trial name
- NCT00002108
- Testing
- Lamivudine, Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV, AIDS
Bioequivalence Study of Pediatric Formulations to Treat HIV Infection
The purpose of the study is to determine the bioavailability/bioequivalence of two pediatric formulations (tablet and reconstitutable suspension) of lamivudine/zidovudine/ nevirapine in comparison to an innovator product.
- Trial name
- NCT01469520
- Testing
- Epivir®, Retrovir® and Viramune®, Lamivudine, Zidovudine and nevirapine, Lamivudine, zidovudine, nevirapine
- Where
- Nigeria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Elim Pediatric Pharmaceuticals Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Patients included in the study with high risk acute myeloid leukemia or myelodysplastic syndrome as defined will receive an allogeneic transplantation conditioned by either myeloablative or reduced regimen.
- Trial name
- VIDAZA-DLI (NCT01541280)
- Testing
- Azacitidine, DLI
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
HIV Infections, Pregnancy
Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies
The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during pregnancy and to their babies after birth.
- Trial name
- NCT00000888
- Testing
- Ritonavir, Lamivudine, Zidovudine
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Chronic
Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients
This is a randomized, open label, phase IV, multicenter study for efficacy and safety of lamivudine versus entecarvir therapy in HBV-related advanced liver disease patients with high viral load and normal or slightly elevated…
- Trial name
- NCT00823550
- Testing
- Entecavir, Lamivudine
- Where
- South Korea
- Volunteers
- 462 people
- Sponsor
- Yonsei University
HIV Infections
A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
This study will assess the effect of food on the pharmacokinetics (PK) of pediatric formulations of TRIUMEQ (dolutegravir [DTG] 5 milligrams [mg]/abacavir [ABC] 60 mg/lamivudine [3TC] 30 mg) dispersible tablets and DOVATO (DTG 5…
- Trial name
- NCT04827134
- Testing
- TRIUMEQ, DOVATO
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection
Retrospective observational study, multicentric with Spanish hospitals, in which a switching or change strategy with RAL and ABC / 3TC guidelines was used, in the48 weeks before the start of the study, in order to determine…
- Trial name
- KIRAL (NCT03158077)
- Where
- 14 sites in Spain
- Volunteers
- 467 people
- Sponsor
- Fundacion SEIMC-GESIDA
Human Immunodeficiency Virus (HIV) Infection
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to <12 years and weighing <45 kg, who are treatment-naive (TN) or have been…
- Trial name
- NCT04375800
- Testing
- Doravirine, 2 NRTIs, DOR/3TC/TDF
- Where
- 26 sites in United States, Colombia and 6 more
- Volunteers
- 84 people
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment
A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)
To assess the ability of lamivudine to lower the levels of neurocognitive impairment biomarkers in the plasma of patients with MCI and positive AD biomarkers in a 24 weeks-treatment period.
- Trial name
- NCT06519357
- Testing
- Lamivudine 300 MG
- Where
- Spain
- Volunteers
- 23 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
HIV
Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC
The primary objective of this study in antiretroviral (ARV)-naïve Human immunodeficiency virus 1 (HIV-1) ribonucleic acid infected subjects is to compare the response rate at Week 48 of a daily regimen of Atazanavir (ATV)/…
- Trial name
- NCT01620944
- Testing
- Atazanavir, Ritonavir, Lamivudine
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients
The purpose of this study is to look at the effectiveness of giving a new anti-HIV drug (AG1549) plus Viracept (nelfinavir) plus Combivir (a tablet containing zidovudine plus lamivudine) to HIV-infected patients who are not…
- Trial name
- NCT00004999
- Testing
- Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate
- Where
- 53 sites in United States, Canada and 2 more
- Volunteers
- 350 people
- Sponsor
- Agouron Pharmaceuticals
HIV Infections
A Study of a Combination of Four Drugs in Patients With Recent HIV Infection
The purpose of this study is to see if it is safe to give a combination of four anti-HIV drugs to patients recently infected with HIV who have never received anti-HIV treatment.
- Trial name
- NCT00002233
- Testing
- Indinavir sulfate, Abacavir sulfate, Amprenavir
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Glaxo Wellcome
HIV Infection, Cardiovascular Disease
HIV Treatment and CVD Events
Cardiovascular disease (CVD) has been associated with HIV infection. However, it is uncertain whether increased CVD rates are associated with HIV-related factors (e.g., HIV-infection or highly active antiretroviral therapy…
- Conditions
- HIV Infection, Cardiovascular Disease, Infection, Human Immunodeficiency Virus, Acute Myocardial Infarction
- Trial name
- NCT01054638
- Testing
- HAART Treatment
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC).
- Trial name
- NCT00002400
- Testing
- Indinavir sulfate, Delavirdine mesylate, Lamivudine
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Pharmacia and Upjohn
HIV Infection
A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
This study was designed to evaluate if subjects who took 600 mg of abacavir and 300 mg of lamivudine once-daily as a single tablet were just as likely to have adverse events compared to subjects who took 300 mg of abacavir and…
- Trial name
- NCT00094367
- Testing
- Abacavir/Lamivudine
- Where
- 178 sites in United States
- Volunteers
- 900 people
- Sponsor
- GlaxoSmithKline
HIV Infections
A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.
To compare the safety, tolerance, early antiviral activity, and durability of antiviral response of the lamivudine (3TC)/zidovudine (ZDV)/1592U89 arm versus the 3TC/ZDV/indinavir (IDV) arm.
- Trial name
- NCT00002199
- Testing
- Indinavir sulfate, Lamivudine/Zidovudine, Abacavir sulfate
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Glaxo Wellcome
Nonmalignant Neoplasm, Tuberous Sclerosis
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
This research study is evaluating a drug called rapamycin as a possible treatment for the lumps (or tumors) that form in the kidneys, called angiomyolipomas, in people who have either TSC or LAM.
- Conditions
- Nonmalignant Neoplasm, Tuberous Sclerosis, Lymphangioleimyomatosis, Kidney Angiomyolipoma
- Trial name
- NCT00126672
- Testing
- Rapamycin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
HIV Infections
Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan
Prospective, Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) Plus Tenofovir Disoproxil Fumarate (TDF) and Lamivudine in a Fixed-Dose Combination Tablet (Combo) for Patients Receiving Co-Formulated TDF…
- Trial name
- NCT03595709
- Testing
- 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)
- Where
- 2 sites in Taiwan
- Volunteers
- 50 people
- Sponsor
- Yu-Jay Corp.
HIV Infection
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy…
- Trial name
- NCT00038506
- Testing
- abacavir/lamivudine/zidovudine, tenofovir
- Where
- 27 sites in United States
- Volunteers
- 100 people
- Sponsor
- ViiV Healthcare